Nektar Therapeutics (NKTR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$38.48+1.91%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · NKTR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -49.4% |
| Our one-year growth estimate | diamond | -1.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 47.6 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 66 industry peers
NKTR — CFO transition
Dated 2026-05-08
interim Chief Financial Officer — Sandra Gardiner: Sandra Gardiner is retiring and stepping down as interim Chief Financial Officer, with Linda Rubinstein succeeding her in the same role.
Why it matters: The alopecia areata trial is the next planned Phase 3 study. Starting on time would advance the path toward the planned 2029 BLA filing.
Supportive ifNektar reports that the 850-patient ZENITH AA Phase 3 study starts in early 2027, as planned.
Worry ifNektar reports that ZENITH AA has not started by the end of early 2027 or that its planned size or main endpoint has changed.
Why it matters: ZENITH AD-3 tests rezpegaldesleukin in patients with prior biologic or JAK treatment. Clear trial progress would support the wider Phase 3 plan.
Supportive ifNektar reports that ZENITH AD-3 is enrolling patients and remains active, with no delay to the Phase 3 program.
Worry ifNektar reports a pause, delayed enrollment, or a change that removes the prior-treatment group from ZENITH AD-3.
Why it matters: The Phase 2 study showed lasting skin and itch responses during treatment. Off-treatment results will test how long those gains last without dosing.
Watch forThe Q1 2027 update reports that patients keep key skin or itch responses through 52 weeks off treatment.
Also watch forThe Q1 2027 update reports that key skin and itch responses fall after treatment stops.
Why it matters: Nektar has $1.02 billion in cash and investments, but it is losing money. Cash use matters as Phase 3 costs rise.
Worry ifThe Nov. 5 report shows cash and investments above $1 billion and a cash runway through Q3 2028 or later.
Less concerning ifThe Nov. 5 report shows cash and investments below $1 billion or a cash runway ending before Q3 2028.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$189 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $680 loss on $10,000 · 6.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,434 loss on $10,000 · 64.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The six-month results showed 63% kept a SALT Score of 20 or less. The 24-week update can test whether that benefit lasts.
Watch forThe Q4 2026 update shows at least 63% of patients still have a SALT Score of 20 or less after 24 weeks off treatment.
Also watch forThe Q4 2026 update shows fewer than 63% still have a SALT Score of 20 or less after 24 weeks off treatment.